Ching Kim Tye
Head of DP Platform and Early Clinical Development Sanofi
With over two decades of global drug development experience, I am a Director and Head of Lipid Nanoparticle (LNP) Platform Development at Sanofi, a leading global biopharmaceutical company. I have led the strategy, planning, and execution of new projects that leverage LNP technology for delivering RNA protein vaccines and the formulation and CMC development of small molecules and peptides.
My areas of expertise include non-viral delivery systems, formulation, process scale-up, technology transfer, CMC strategy, and Regulatory CMC submissions. I have a track record of building and leading high-performing R&D teams, managing external partnerships and collaborations, and optimizing R&D resources and infrastructure. I am passionate about developing innovative drug delivery solutions to improve patients’ lives and address unmet medical needs. I also champion diversity, equity, and inclusion in the scientific community.
Seminars
Key questions include:
- How are teams successfully translating high-throughput, discovery-stage LNP workflows into robust, GMP-ready processes without compromising product quality?
- Where do current LNP workflows break when moving from preclinical into clinical and commercial scale – and how can these gaps be addressed early?
- What needs to change today to ensure LNP platforms remain scalable, reproducible, and cost-effective as products move toward global commercial supply?
- Developing scalable, semi-automated workflows to streamline mRNA and LNP production from plasmid DNA through to encapsulated product for rapid preclinical evaluation
- Leveraging liquid handling systems and high-throughput screening platforms to accelerate formulation optimization while maintaining material quality suitable for in vivo studies
- Sharing lessons learned from translating mRNA and LNP processes across bench-scale, GMP manufacturing, and miniaturized automated screening systems
